Back

NBIX Stock

Price Chart

📈
Loading chart for NBIX...
Powered by TradingView

Detailed Market Analysis

Key Levels

Support
$125.02
Resistance
$138.18

Volume & Momentum

Volume
Weak
0.8x avg
Momentum
0%
Weak

Trading Setup

HOLD
Entry $131.60
Stop $125.02
Target $138.18
RSI: 50 | Current: $131.60

Market Sentiment

50
Neutral

Stock Metrics

Daily Vol
0%
VIX Est
20
Weekly
0%

Insider Trading

Insider Role Date Type Value
ABERNETHY MATT Chief Financial … Feb 13 '26 Option Exercise 0.0
ABERNETHY MATT Chief Financial … Feb 12 '26 Option Exercise 0.0
Boyer David W. Chief Corp. … Feb 13 '26 Option Exercise 0.0
Boyer David W. Chief Corp. … Feb 12 '26 Option Exercise 0.0
Gano Kyle Chief Executive … Feb 13 '26 Option Exercise 0.0
Gano Kyle Chief Executive … Feb 12 '26 Option Exercise 0.0
Onyia Jude Chief Scientific … Feb 13 '26 Option Exercise 0.0
Onyia Jude Chief Scientific … Feb 12 '26 Option Exercise 0.0
BENEVICH ERIC Chief Commercial … Feb 13 '26 Option Exercise 0.0
BENEVICH ERIC Chief Commercial … Feb 12 '26 Option Exercise 0.0

Source: FinViz — Data may be delayed

NBIX News Intelligence (1 articles)

AI-curated news influencing NBIX price, sentiment, and trend

Explore All NBIX News with AI Analysis
Global Markets & Finance
4 hours, 4 minutes ago

Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment

Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome

Impact on NBIX: The acquisition is likely to have a positive impact on Neurocrine's stock …
Neurocrine is nearing a $2.5bn-plus deal to acquire Soleno Therapeutics, the biotech company behind the … High (80%)
View full analysis →
Financial Times 80% confidence
🤖

AI Analysis

Multi-Provider AI Analysis

Neutral

AI Summary

Loading...

Confidence
0%
AI Model Multi-Provider AI Analysis
Open article